Kiadis Still Betting On Blood Cancer Immunotherapy Launch This Year

 
• By Ian Schofield

Kiadis has conducted further analyses of data on its investigational blood cancer therapy ATIR101 and is now hoping to secure EU approval in time for the therapy to be used in the first patients by the end of 2019.

PS1812_Cancer Treatment_362582462_1200.jpg
Kiadis hopes for EU approval of its blood cancer therapy this year.

More from Product Reviews

More from Pink Sheet